April 22nd 2024
Based on the classes' cardio- and renoprotective benefits, the ACP recommends SGLT2i and GLP1RA as second-line therapy in adults with T2D who are most likely to benefit.
Metabolically Healthy Obesity May Increase Risk of Heart Failure, but Not Heart Attack or Stroke
October 5th 2021EASD 2021: Patients with metabolically healthy obesity are nearly 33% more likely to develop heart failure and atrial fibrillation than healthy persons of normal weight, suggests new analysis.